Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It
Debate At CTAD Underscores Doctors’ Dilemma
The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.
You may also be interested in...
With CMS draft decision expected next month on amyloid-clearing antibodies for Alzheimer’s, Biogen slashes Aduhem’s price 50% to $28,200 per year. Move reverses another aspect of the approval that drew criticism, including the expansive label and long horizon for confirmatory data.
The Alzheimer’s drug’s price was cut to $28,200 per year just one month before CMS is expected to issue a draft national coverage determination for amyloid-clearing antibodies, raising questions about the timing.
In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.